Skip to main content

Bee venom allergy immunotherapy

Anaphylaxis: case report

This is a preview of subscription content, access via your institution.


  • Da Silva EN, et al. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. Journal of Allergy and Clinical Immunology: In Practice 1: 687-688, No. 6, Nov 2013. Available from: URL: - Australia

    Google Scholar 

Download references

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bee venom allergy immunotherapy. Reactions Weekly 1483, 21 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI: